Recently, CD200 has been proposed as a marker for CAFs in lung cancer, and it has been shown that high expression of CD200 in CAFs increases their sensitivity to EGFR/TKI inhibitors, such as Gefitinib, and induces cancer cell apoptosis. This evidence concerns the gene EGFR and lung cancer.